Christopher Visit 2: 54-year-old male with family history of diabetes and elevated A1C, 3-month follow-up

Title:	Christopher Visit 2: 54-year-old male with family history of diabetes and elevated A1C, 3-month follow-up
Topic:	Diabetology
Relevant Terms:	Cardiometabolic Risk, Diabetes, Dyslipidemia, Endocrinology, Macrovascular Disease, Microvascular Disease, Type 2 Diabetes
Primary Audience:	Primary care providers (MDs/ DOs/ NPs/ PAs) and other healthcare professionals who treat adults with diabetes
Launch Date:	08-Feb-10
Credits:	0.5 AMA PRA Category 1 Credit™
Expiration Date:	31-Dec-12

Enter this activity!

Learning Objectives

Upon completion of the activity, participants should be able to:

Identify key practice and type 2 diabetes management issues at the core of consultative treatment interactions between specialty and primary care practices
Describe evidence-based recommendations regarding treatment goals and methods of therapy addressed by type 2 diabetes treatment guidelines
Assess educational needs of primary care providers and specialist support gaps based on an evaluation of consultative referrals
Utilize evaluation described above to design and implement improved systems for enhancing the efficacy and efficiency of consultative interactions related to diabetes management

Faculty

Om P. Ganda, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Director, Lipid Clinic
Joslin Diabetes Center
Boston, MA

Paul S. Jellinger, MD, MACE
Professor of Medicine, Voluntary Faculty
University of Miami
Past President
American College of Endocrinology
American Association of Clinical Endocrinologists
Miami, FL

Paul S. Jellinger, MD, MACE

Dr. Jellinger is Past President of the American Association of Clinical Endocrinologists (AACE) and Past President of the American College of Endocrinology (ACE). He is Professor of Medicine on the voluntary faculty at the University of Miami. In May 2004, he became a Master of the American College of Endocrinology (MACE).

After receiving his medical degree from Wayne State University School of Medicine, Dr. Jellinger completed a first-year medical residency at Beth Israel Hospital and a second-year residency at Mount Sinai Hospital in New York City. He subsequently was awarded an NIH fellowship in Endocrinology at Mount Sinai Hospital. Dr. Jellinger has served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. He is involved in many regional and national professional and scientific associations including The Endocrine Society and the American Diabetes Association and is Past President of The Florida Endocrine Society. Dr. Jellinger is board-certified in internal medicine and endocrinology and metabolism. He has also conducted investigative research on over 50 subjects and is currently conducting research for several major pharmaceutical companies. Dr. Jellinger currently serves as Medical Editor of Clinical Endocrinology News.

Dr. Jellinger, who was a founding member, was elected President of the American Association of Clinical Endocrinologists, a 5500-physician member organization, in May 2000. He has been active on the AACE Board of Directors and has served as chairman of several committees including the Clinical Research Committee. Dr. Jellinger was also a member of the task forces that defined and published the AACE Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus, AACE Medical Guidelines for Clinical Practice for Evaluation and Treatment of Hyperthyroidism and Hypothyroidism, and the AACE Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. He served as Chairman of the Task Force for the AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis. He was a participant in both the 2001 and 2002 ACE/AACE Consensus Conferences on Glycemic Control and the Insulin Resistance Syndrome and was Co-Chairman of the 2005 ACE/AACE Diabetes Consensus Conference on Implementation of Glycemic Goals. He is co-author of the recently published ACE/AACE Roadmap for the Prevention and Treatment of Type 2 Diabetes and was a contributing author to the recently published ACE/AACE Guidelines for the Treatment of Diabetes Mellitus. He served as a Task Force and Writing Committee member of the recently published 2008 Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia-When Do the Risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists and is Co-Chair of the ACE/AACE Diabetes Treatment Algorithm Task Force. Dr. Jellinger lectures frequently on topics related to diabetes mellitus and lipid disorders.

Bernard Zinman, MD, MDCM, FACP, FRCP
Professor of Medicine
University of Toronto
Director, Leadership Sinai Centre for Diabetes
Mount Sinai Hospital
Toronto, Ontario, Canada

Bernard Zinman, MD, MDCM, FACP, FRCP Dr. Zinman is Director of the Leadership Sinai Centre for Diabetes and holds the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto, Canada. He is Professor of Medicine at the University of Toronto and Senior Scientist at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Dr. Zinman was Director of the Banting and Best Diabetes Centre (1993-2000) and is involved with diabetes care and research at both national and international levels. Dr. Zinman is Principal Investigator of the University of Toronto Centre and Vice-Chair of the DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications) study.

Dr. Zinman graduated MDCM from McGill University in Montreal, where he also received his postgraduate training in internal medicine. He undertook further training in Endocrinology at the University of Toronto.

Dr. Zinman has written more than 300 publications in national and international journals, and over 60 book chapters and editorials. He is the recipient of numerous awards including the Charles H. Best Medal for Distinguished Service in the Cause of Diabetes (awarded to the DCCT Investigators), the Alois Beringer Lecture Award, the Frederick G. Banting Award, and the Gerald S. Wong Service Award of the Canadian Diabetes Association (CDA). In November 2000, Dr. Zinman chaired the scientific program committee of the 17th International Diabetes Federation Congress held in Mexico City. In August 2003, Dr. Zinman delivered the Banting and Best Memorial Lecture at the International Diabetes Federation Congress in Paris, France. In 2006 Dr. Zinman received the American Diabetes Associations Outstanding Physician Clinician Award.

His main research interests include the long-term complications of diabetes mellitus, the development of new therapies for type 1 and type 2 diabetes, diabetes in Aboriginal communities, and studies directed at the prevention of diabetes.

Planning Committee:

Richard S. Beaser, MD

Associate Clinical Professor of Medicine

Harvard Medical School

Medical Executive Director

Professional Education

Joslin Diabetes Center

Boston, MA

Julie Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA

James Neighbours, MEd
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA

DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.

Dr. Ganda is on the speakers bureau for Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Kos Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer Inc, sanofi-aventis U.S. LLC and Takeda Pharmaceuticals North America, Inc.; receives grant/research support from Eli Lilly and Company; and is a consultant for Daiichi Sankyo, Inc.
Dr. Jellinger is on the speakers bureau for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk Inc., and Takeda Pharmaceuticals North America, Inc.
Dr. Zinman is a consultant for Amylin Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; is a consultant and on the speakers bureau for Eli Lilly and Company; and receives grant/research support from, is a consultant for and is on the speakers bureau for GlaxoSmithKline, Merck & Co., Inc., and Novo Nordisk Inc.
Dr. Beaser is on the academic advisory boards for AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Novo Nordisk Inc.
Ms. Brown has no relevant financial relationships.
Mr. Neighbours has no relevant financial relationships.

ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score with a 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS

PC
Internet Explorer (v6 or greater), or Firefox

MAC
Safari

Release Date: February 8, 2010
Expiration Date: December 31, 2012

ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.

This activity is supported by an educational grant from Pfizer Inc.

If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.

Copyright © 2010 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.

Enter this activity!